The identification of nicotinamide-N1-oxide as a metabolite in the urine of a schizophrenic patient prompted a study of the relative metabolism of nicotinic acid and nicotinamide in mental patients and healthy volunteers. Metabolites quantified included N'-methyl-2-pyridone-5-carboxamide, N1-methyl-4-pyridone-3-carboxamide, N1-methylnicotinamide, nicotinuric acid, and nicotinamide-N1-oxide. More of most of these metabolites evidently was excreted after nicotinamide ingestion than after nicotinic acid. At the highest doses (3000 mg/day), the relative proportions of these metabolites in the urine were changed. There were only slight differences between healthy individuals and mental patients in the quantities of metabol'ttes excreted, and no statistically significant trends were noted. (1) and is also a metabolite in germ-free rats, indicating that, in these species at least, it is a product of endogenous metabolism (2). Although this compound had been previously inferred to be a normal metabolite in humans, its identity had not been established conclusively (3).
The identification of nicotinamide-N1-oxide as a metabolite in the urine of a schizophrenic patient prompted a study of the relative metabolism of nicotinic acid and nicotinamide in mental patients and healthy volunteers. Metabolites quantified included N'-methyl-2-pyridone-5-carboxamide, N1-methyl-4-pyridone-3-carboxamide, N1-methylnicotinamide, nicotinuric acid, and nicotinamide-N1-oxide. More of most of these metabolites evidently was excreted after nicotinamide ingestion than after nicotinic acid. At the highest doses (3000 mg/day), the relative proportions of these metabolites in the urine were changed. There were only slight differences between healthy individuals and mental patients in the quantities of metabol'ttes excreted, and no statistically significant trends were noted. During the examination of the urine from a patient with schizophrenia, we identified the compound nicotinamide-N'-oxide. This compound is a quantitatively important urinary metabolite of nicotinic acid in the mouse (1) and is also a metabolite in germ-free rats, indicating that, in these species at least, it is a product of endogenous metabolism (2) . Although this compound had been previously inferred to be a normal metabolite in humans, its identity had not been established conclusively (3).
We undertook the present study (a) to estimate the relative importance of this compound as a metabolite of nicotinic acid and nicotinamide in humans, and (b) to ascertain if there are differences in the metabolism of nicotinamide and nicotinic acid by schizophrenic patients as compared to healthy individuals.
Materials and Methods

Subjects and Materials
Three healthy men, varying in age from 32 to 63 and in weight from 68 to 82 kg, were studied. Two of the individuals ingested single doses of nicotinic acid and nicotinamide ranging from 100 to 1000 tng at intervals of several days. The third individual ingested single doses of 1000 and 3000 mg of nicotinamide.
We also examined samples from two other men, with hypertensive heart disease and hyperlipidemia, each of whom had received 3000 mg of nicotinic acid daily for several months.
Urine from eight institutionalized male patients (age, 21 to 63 y) displaying various forms of schizophrenia or psychoses after chronic alcohol addiction was also studied. Several of these patients had been placed on a therapeutic regime of 3000 mg of nicotinamide daily for 3 to 5 d.
All urine samples for analyses were collected during the succeeding 24 h after nicotinamide or nicotinic acid ingestion.
No preservative was added. All specimens were stored at -20 #{176}C until analyzed.
Analytical Methods
An Oak Ridge National Laboratory high-resolution liquid-chromatographic UV-Analyzer was used for all analyses. The methods were essentially the same as described previously (4, 5) . The analyzer was interfaced to a PDP-8/I minicomputer for on-line determination of elution volumes, absorbance ratios (254/280 nm), peak areas, and resolution of multipeak envelopes as reported elsewhere (6). A 0.62 X 150 cm column containing "Aminex A-27" anion-exchange resin (12-to 15-rim particle diameter; Bio-Rad Laboratories, Richmond, Calif. 94804) was used for most analyses. In most studies a 0.74 X 13 cm column containing Aminex A-5 Elution of the drug-related peaks nicotinamide and N'-methylnicotinamide (shaded) has been retarded by the cation column cation-exchange resin (12-to 15-tim particle diameter) was placed on top of the main anion-exchange column to produce a coupled-column system. This modification improved resolution at the front of the chromatogram by retarding the elution of N1-methylnicotinamide, creatinine, and nicotinamide ( Figure 1 ). The improved resolution permitted complete separation of creatinine and N1-methylnicotinamide, which are coeluted as a single peak in the absence of the cation-exchange column (Figure 1 ). In the latter case, the interference of creatinine in the analysis for N'-methylnicotinamide was eliminated by analyzing for the latter compound at 290 nm, where the absorbance of creatinine is negligible.
To determine the linearity of chromatographic peak area with the concentration of sample, we analyzed serial dilutions of a reference urine specimen. The computer-integrated areas were plotted vs. sample concentrations for compounds representing four different ranges of peak area (Figure 2 ). Peak areas were quite linear, with little scatter being observed down to areas of the order of 2 ml h/mol cm. This value would represent about 1 and 3 ig of uracil and pseudouridine, respectively. The scatter for smaller peaks (0.1 to 0.5 ml h/mol cm, as produced, e.g., by 100 to 1000 ng of orotic acid) indicates that precise quantification of extremely small peaks should not be considered. In this study, the peak areas were generally in excess of 0.03 liter h/mol cm. The wide scatter of the peak areas for creatinine ( Figure 2 ) is due to two factors: (a) the early elution of this compound in a region of unstable pH and (b) the use of the 254-nm wavelength for monitoring, which lies on an extremely steep side of the absorption band for this compound. The molar absorptivity of creatinine (at this point in its absorption spectrum) is very dependent on PH; differences as small as 0.1 pH unit do cause significant changes. With the coupled-column system (Figure 1 ), the precision of creatinine measurements is greatly improved, and the results are in close agreement with those derived by the Jaff#{233} reaction with picric acid.
The coupled-column system had little influence on the area of the other peaks.
To determine the accuracy of the system for quantification of compounds, we chromatographed known amounts of selected reference compounds (together with 50 l of a composite reference urine, to study matrix effects) on the coupled-column system under our usual conditions. Peaks in the resulting chromatograms were quantified by the use of molar absorptivity data, computer-determined areas, and flow rates. Recoveries for several compounds that were important in this study (e.g., N'-methylnicotinamide, nicotinic acid, nicotinamide, nicotinuric acid, and nicotinamide-N1-oxide) averaged 99.8%, with a coefficient of variation of 5.1%. The correlation coefficient between uric acid determined by a colorimetric method (phosphotungstate reduction) and by the liquid chromatographic system was 0.963. Most of the results obtained chromatographically were lower, as could be anticipated from the known nonspecificity of the colorimetric procedure.
Results
The excretion of the metabolites of nicotinic acid and nicotinamide by the healthy individuals and the two cardiac patients is illustrated graphically in Figure 3 . The excretory patterns of the two heart patients and six of the schizophrenic patients were similar after the ingestion of 3000 mg of nicotinic acid and are probably the same as would be the case for normal persons.
The normal excretion rates of the metabolites
and nicotinamide-N1-oxide) were higher for the subjects who ingested nicotinamide than for those receiving nicotinic acid when single doses of up to 1000 mg were administered daily to both groups ( Table 1 ). The excretion of N1-methyl-2-pyridone-5-carboxamide (the major metabolite within this dosage range) showed the greatest change, increasing by about 50% when compared with the excretion after nicotinic acid ingestion. When 3000 mg of nicotinic acid or nicotinamide was ingested, N1-methylnicotinamide excretion exceeded that of the 2-pyridone; in the case of healthy individual and nine schizophrenics is compared after they each ingested a single 3000-mg dose of nicotinamide. The absolute excretion of the different metabolites by the schizophrenics varies widely. The average analytical recovery was 43% of the ingested dose for the schizophrenics, compared with 57% for the healthy individual [same percentage recovery as when he ingested only 1000 mg of nicotinamide (Table 2) ]. The excretion of metabolites by schizophrenic C is of interest because he excreted much more of the N1 -oxide than did any other individual and at the same time excreted one of the lowest quantities of the 2-pyridone. His excretion of NLmethylnicotinamide was only 9% less than that of the healthy individual. Interestingly, schizophrenic C was the only subject who had a type of schizophrenia that appeared to be genetically inherited. Liver-function tests performed on this patient demonstrated no abnormality.
The influence of long-term ingestion of 3000 mg of nicotinic acid was studied in five schizophrenics, two
A Percentage of administered drug recovered as urinary metabolites in 24 nicotinic acid ingestion, nicotinuric acid became the major metabolite. Lower excretion rates of nicotinamide-N1-oxide were observed in individuals receiving nicotinic acid as compared with those receiving nicotinamide. This may be due to the detoxifying conversion of nicotinic acid to nicotinuric acid, coupled with a rate-limited conversion of nicotinic acid to nicotinamide.
When the excretion of metabolites by the cardiac subjects after nicotinic acid ingestion is compared with that in the one healthy individual after the same dose of nicotinamide, it is noteworthy that the total recovery of metabolites is 74 and 87% in the cardiac patients compared with 57% for the normal person. This may 
ExcretIon of Metaboiltes by SchizophrenIcs and a Normal Subject after Ingestion of 3000 mg of Nicotlnamide
Excretion rate, mg/24 h chronic alcoholic patients with severe psychoses, and the two hypertensive patients. The pattern of metabolite excretion for the subjects was similar (Table 4) This individual excreted less of the pyridone but increased amounts of both nicotinamideNLoxide and N1-methylnicotinamide (similar to schizophrenic C after ingestion of nicotinamide, as illustrated in Table 3 ). In all cases, the analytical recovery of metabolites within 24 h of ingestion of the nicotinic acid was between 72 and 88% of the ingested amount. Figure 4 shows the major metabolic pathways for nicotinic acid and nicotinamide. This diagram includes N1 -ribosyl-2-pyridone-5-carboxamide, which 'has not been reported previously, but which we observed to be excreted to the extent of 5 to 10 mg/d in normal individuals on an unrestricted diet. The identity of this 
Discussion
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H OH latter compound was confirmed after completion of our study on the metabolism of nicotinic acid and nicotinamide. Details of its identification and potential significance in the metabolism of nicotinic acid will be discussed elsewhere.
The data in Table 1 and Figure 3 indicate that, with the exception of an increased excretion of nicotinuric acid following the ingestion of nicotinic acid, little difference is noted in either quantities or identities of metabolites regardless of whether the acid or the amide is ingested. This is in keeping with the belief that nicotinic acid is rapidly conjugated with glycine to produce nicotinuric acid or is converted to nicotinamide. After the ingestion of nicotinamide, normal A excreted a much greater quantity of N1-methylnicotinamide than did the other two normal persons (B and C) or the schizophrenic patients (see Table 2 ). This may reflect higher methylase activity within this individual.
Although nicotinamide-N1-oxide was not detected in the urine of well individuals or of schizophrenic patients on an unrestricted diet, it was present in the urine of all subjects studied when nicotinic acid or nicotinamide was ingested. Thus it is probably unrelated to the schizophrenic state per Se. However, some of the schizophrenic individuals appeared to differ from both the majority of the other patients and the healthy individuals in their response to the ingestion of nicotinic acid. Thus, schizophrenic D excreted about half of the quantity of the two pyridones and fourfold as much nicotinamide-N1-oxide as compared with the average of all other individuals who had ingested 3000 mg of nicotinic acid for at least three days. He also excreted slightly more N1 -methylnicotinamide.
These results, which are similar to those of schizophrenic C after ingestion of nicotinamide (Table 3) , seem to indicate a diminished capacity to convert N1-methylnicotinamide into the two pyridone derivatives. This is the normal metabolic pathway in experimental animals and, probably, in humans. The two pyridones were formed under the catalytic influence of aldehyde oxidase, as illustrated in Figure 3 . Most of the examined subjects showed a relatively constant ratio of 2-pyridone to 4-pyridone, ranging from 5.3/1 to 6.3/1. A much greater ratio (8.5/1) was shown by schizophrenic I, while heart-patient B and schizophrenic D showed much lower values. Long-term therapy did not appear to cause any change in the ratio. Nicotinamide metabolism is not the same in all species; therefore, extrapolation from experimental animals to the human is not necessarily valid. It has been demonstrated that the 2-pyridone is a quantitatively important metabolite in man, but not in the dog, cat, or rat (8) . Although xanthine oxidase (EC 1.2.3.2) has been implicated to explain the variable ratio of excretion of the two pyridones in the rat (7), there is no proof at present that this is the causative factor in humans. Evidence has been presented to indicate a lesser excretion of the 2-pyridone in schizophrenics (9). Our data indicate a possible reduction in the quantity excreted by schizophrenics without nicotinic acid or nicotinamide therapy, although dietary differences alone may account for this. After ingestion of 3000 mg of nicotinamide, most of the schizophrenic patients excreted much less than did the one healthy control. However, for most of the patients, the ratio of 2-pyridone to 4-pyridone excreted in the urine was about 6/1. Only one subject, schizophrenic I, excreted a disproportionately greater quantity as compared with the healthy individuals (who manifested the same ratio as most of the schizophrenics). In this individual, there may be an actual (or greater) participation of xanthine oxidase in the metabolism of N'-methylnicotinamide.
In heart-patient B and schizophrenic B, it is possible that xanthine oxidase is assuming a less important role than normal. Additionally, this enzyme may become more significant in the metabolism of nicotinamide as the dose of the vitamin is increased, as suggested by the data in Figure   Research sponsored by the National Institute of General Medical Sciences, NIH, Bethesda, Md.
